Bose Wins Global Supplier Award from Nissan for Automotive Innovation
Nissan Motor Corporation has selected Bose for a 2017 Global Supplier Award in the field of automotive innovation for creating the first-of-its-kind Bose® Personal® sound system in the all-new Nissan Micra.
Each year, Nissan recognizes quality, excellence, and innovation from its global network of suppliers. And Bose is just one of eight suppliers -- among the thousands of companies working with Nissan -- spotlighted this year as a key contributor to the auto maker’s efforts to increase product competitiveness through innovative offerings.
“We are incredibly honored to receive this award from Nissan,” said Marc Mansell, vice president, Bose Automotive Systems. “We have a dedicated team of people who work very hard -- obsessing over every detail -- to create new technologies and products that people love. It’s what we strive for every day. So, it is tremendously rewarding to earn this kind of recognition.”
This is the second time in three years that Bose has been recognized by Nissan for supplier excellence. In 2015, Bose won a Global Quality Award for its contributions in the field of automotive electronics.
ABOUT THE BOSE PERSONAL SOUND SYSTEM
The award-winning Bose
Personal system sets a new standard for small-car audio by delivering a
superior, driver-focused listening experience inside the compact cabin
of the fully re-designed Micra, which debuted in Europe in the spring of
2017.
Optimized for the driver’s seat -- the only cabin position occupied 100 percent of the time -- the Bose Personal system uses Bose UltraNearfield™ headrest speakers, combined with Bose PersonalSpace™ Virtual Audio Technology, to produce a wide sound field with musical clarity and depth that would otherwise require far more speakers. The Bose Personal system in the Micra has just six speakers in total, including the two in the driver’s seat headrest.
Bose has provided custom-engineered audio systems and technologies to Nissan vehicles for nearly 30 years. For more information about the Bose Personal system, visit BoseSmallVehicle.co.uk
ABOUT BOSE AUTOMOTIVE SYSTEMS
In the early 1980s, Bose engineers
created the world’s first factory-installed premium automotive sound
systems. Unlike conventional or aftermarket automotive systems, Bose
systems were designed and tuned for a specific vehicle -- and changed
the industry. Since then, Bose has developed proprietary speaker
designs, advanced amplification and signal processing technologies,
exclusive analysis and design tools, and technology for managing
engine and powertrain sounds inside vehicles -- all based on a heritage
of research and engineering.
Today, Bose automotive sound systems are recognized globally as the industry benchmark for performance and customer satisfaction, validated by independent research rating Bose as the top choice among car consumers in multiple global regions. For more information, visit BoseAutomotive.com.
ABOUT BOSE CORPORATION
Bose Corporation was founded in 1964 by Dr.
Amar G. Bose, then a professor of electrical engineering at the
Massachusetts Institute of Technology. Today, the company is driven by
its founding principles, investing in long-term research with one
fundamental goal: to develop new technologies with real customer
benefits. Bose innovations have spanned decades and industries, creating
and transforming categories in audio and beyond. Bose products for the
home, in the car, on the go and in public spaces have become iconic,
changing the way people listen to music.
Bose Corporation is privately held. The company’s spirit of invention, passion for excellence, and commitment to extraordinary experiences can be found around the world -- everywhere Bose does business.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170713005492/en/
Contact information
Bose
Kevin Doak, 508-766-7788
kevin_doak@bose.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom